You might also like
Artiva Biotherapeutics, Inc. is a biotechnology company founded in 2019 that focuses on developing and commercializing innovative therapies for autoimmune diseases and other medical conditions. The company specializes in research and development, manufacturing, and regulatory activities to advance its product candidates, particularly in the area of AlloNK cell therapies. Artiva's operations also include collaborations, intellectual property management, and preparation for potential product commercialization.
- AlloNK Cell Therapies - Develops and advances natural killer (NK) cell-based therapies for autoimmune diseases and other indications, focusing on clinical and preclinical development.
- License and Development Support Agreements - Generates revenue through agreements that provide licensing and development support for its product candidates.
- Manufacturing and Logistics - Establishes and scales up manufacturing processes and cold chain delivery logistics for its therapies.
- Collaborations and Intellectual Property - Engages in partnerships and actively manages intellectual property to support its business objectives.
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
This company is identified as a competitor in the development of allogeneic CAR-NK or CAR-T cell therapies or T-cell engaging bispecific antibodies, which are areas of focus for the company. | |
This company is listed among the competitors in the biopharmaceutical industry, particularly in the development of allogeneic CAR-NK or CAR-T cell therapies. | |
This competitor is noted for its involvement in developing targeted therapies, including those that overlap with the company's focus on cell-based therapies. | |
This company is mentioned as a competitor in the field of CAR-T cell therapies, which are relevant to the company's product development. | |
This competitor is highlighted for its expertise in biopharmaceuticals and its potential overlap in developing therapies targeting similar indications. | |
This company is identified as a competitor in the development of cell-based therapies, particularly in autoimmune and oncology indications. | |
Candid Therapeutics, Inc. | This competitor is noted for its work in the development of innovative therapies that may compete with the company's pipeline. |
This company is listed as a competitor in the biopharmaceutical space, particularly in the development of CAR-NK or CAR-T cell therapies. | |
This competitor is mentioned for its involvement in developing cell-based therapies, which are relevant to the company's focus areas. | |
This company is identified as a competitor in the development of allogeneic cell therapies, which overlap with the company's product development efforts. | |
This competitor is noted for its work in the biopharmaceutical industry, particularly in areas that may compete with the company's pipeline. | |
This company is highlighted as a competitor in the development of NK cell-based therapies, which directly aligns with the company's focus. | |
This competitor is mentioned for its involvement in developing therapies that may overlap with the company's focus on autoimmune and oncology indications. | |
This company is listed as a competitor in the biopharmaceutical industry, particularly in areas relevant to the company's pipeline. | |
Gracell Biopharmaceuticals, Inc. | This competitor, acquired by AstraZeneca, is noted for its work in cell-based therapies, which may compete with the company's products. |
This company is identified as a competitor in the development of therapies targeting similar indications as the company's pipeline. | |
iCell Gene Therapeutics Inc. | This competitor is mentioned for its involvement in developing innovative cell-based therapies, which are relevant to the company's focus. |
ImmPACT Bio USA, Inc. | This company, acquired by Lyell Immunopharma, Inc., is highlighted as a competitor in the field of cell-based therapies. |
ITabMed Co., Ltd. | This competitor is listed for its work in developing therapies that may overlap with the company's focus on autoimmune and oncology indications. |
This company is noted as a competitor in the biopharmaceutical industry, particularly in areas relevant to the company's pipeline. | |
Kyverna Therapeutics, Inc. | This competitor is identified for its involvement in developing cell-based therapies, which are relevant to the company's focus areas. |
Luminary Therapeutics, Inc. | This company is mentioned as a competitor in the development of innovative therapies that may compete with the company's pipeline. |
This competitor is highlighted for its expertise in biopharmaceuticals and its potential overlap in developing therapies targeting similar indications. | |
This company is listed as a competitor in the development of NK cell-based therapies, which directly aligns with the company's focus. | |
This competitor is noted for its work in the biopharmaceutical industry, particularly in areas that may compete with the company's pipeline. | |
This company is identified as a competitor in the development of therapies targeting similar indications as the company's pipeline. | |
Roche | This competitor is mentioned for its involvement in developing therapies that may overlap with the company's focus on autoimmune and oncology indications. |
This company is highlighted as a competitor in the development of cell-based therapies, which are relevant to the company's focus. | |
This competitor is listed as a competitor in the biopharmaceutical industry, particularly in areas relevant to the company's pipeline. | |
Shoreline Biosciences Inc. | This company is identified as a competitor in the development of allogeneic cell therapies, which overlap with the company's product development efforts. |
Synthekine Inc. | This competitor is noted for its work in the biopharmaceutical industry, particularly in areas that may compete with the company's pipeline. |
This company is mentioned as a competitor in the development of therapies targeting similar indications as the company's pipeline. | |
Wugen, Inc. | This competitor is highlighted for its involvement in developing innovative therapies that may compete with the company's products. |
This company is listed as a competitor in the development of cell-based therapies, which are relevant to the company's focus areas. |
Recent press releases and 8-K filings for ARTV.
- Q1 2025 Financial Highlights: Reported a net loss of $20.3 million and maintained $166.0 million in cash, cash equivalents, and investments, which is expected to fund operations into Q2 2027.
- Clinical Trial Developments: Initiated regulatory submissions and launched a global basket trial exploring AlloNK+rituximab across refractory autoimmune diseases, marking the first U.S. company-sponsored trial for rheumatoid arthritis and Sjögren’s disease.
- Increased Investments in R&D: Reported research and development expenses of $17.1 million, alongside increased general & administrative costs, reflecting ongoing investment in innovative cell therapy programs.
- Financial Position: Artiva reported full year 2024 results with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, which is expected to fund operations through at least the end of 2026.
- Business Developments: The company highlighted strategic updates including an expanded board and bolstered leadership, along with upcoming milestones for its AlloNK® program — with initial autoimmune data expected in H1 2025 and updated NHL clinical results to be presented in 2025.